Coherus BioSciences Inc Net Assets
Coherus BioSciences Inc net assets. Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has net assets worth $60.84 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($191.18 Million) and total liabilities ($130.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Coherus BioSciences Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $60.84 Million |
| % of Total Assets | 31.82% |
| Annual Growth Rate | 15.67% |
| 5-Year Change | -37.57% |
| 10-Year Change | 215.25% |
| Growth Volatility | 218.68 |
Net Assets of Coherus BioSciences Inc (2012–2025)
Net assets of Coherus BioSciences Inc from 2012 to 2025. This chart illustrates how Coherus BioSciences Inc's net assets have evolved over time, based on quarterly financial data. See Coherus BioSciences Inc (CHRS) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Coherus BioSciences Inc (2012–2025)
The table below shows the annual net assets of Coherus BioSciences Inc from 2012 to 2025. For live market cap and overall valuation, see CHRS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $61.01 Million | +146.23% |
| 2024-12-31 | $-131.99 Million | +31.76% |
| 2023-12-31 | $-193.43 Million | -40.76% |
| 2022-12-31 | $-137.42 Million | -240.62% |
| 2021-12-31 | $97.73 Million | -65.22% |
| 2020-12-31 | $280.97 Million | +167.05% |
| 2019-12-31 | $105.21 Million | +372.64% |
| 2018-12-31 | $-38.59 Million | -226.38% |
| 2017-12-31 | $30.54 Million | +57.77% |
| 2016-12-31 | $19.35 Million | +379.32% |
| 2015-12-31 | $-6.93 Million | -110.38% |
| 2014-12-31 | $66.76 Million | +257.51% |
| 2013-12-31 | $-42.38 Million | -561.07% |
| 2012-12-31 | $9.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Coherus BioSciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 133701200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Coherus BioSciences Inc Net Assets Breakdown (December 2025)
Coherus BioSciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.02% |
| Other Comprehensive Income | $-195.00K | -0.32% |
| Other Components | $1.44 Billion | 2366.94% |
| Total Equity | $61.01 Million | 100.00% |
Coherus BioSciences Inc Competitors by Market Cap
The table below lists competitors of Coherus BioSciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Founding Construction Development Co Ltd
TW:5533
|
$124.47 Million |
|
BAOZUN INC. A DL -0001
F:2BZ
|
$124.51 Million |
|
Synalloy Corporation
NASDAQ:ACNT
|
$124.55 Million |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
$124.58 Million |
|
Duluth Holdings Inc
NASDAQ:DLTH
|
$124.30 Million |
|
Argent
JSE:ART
|
$124.29 Million |
|
Moens Bank A/S
CO:MNBA
|
$124.23 Million |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
$124.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Coherus BioSciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -131,990,000 to 61,014,000, a change of 193,004,000.
- Net loss of 170,291,000 reduced equity.
- New share issuances of 7,894,000 increased equity.
- Other comprehensive income increased equity by 80,000.
- Other factors increased equity by 355,321,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-170.29 Million | -279.1% |
| Share Issuances | $7.89 Million | +12.94% |
| Other Comprehensive Income | $80.00K | +0.13% |
| Other Changes | $355.32 Million | +582.36% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Coherus BioSciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.25x to 1.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $3.25 | $0.81 | x |
| 2013-12-31 | $-2.34 | $0.81 | x |
| 2014-12-31 | $8.15 | $0.81 | x |
| 2015-12-31 | $-0.19 | $0.81 | x |
| 2016-12-31 | $0.46 | $0.81 | x |
| 2017-12-31 | $0.57 | $0.81 | x |
| 2018-12-31 | $-0.59 | $0.81 | x |
| 2019-12-31 | $1.44 | $0.81 | x |
| 2020-12-31 | $3.37 | $0.81 | x |
| 2021-12-31 | $1.30 | $0.81 | x |
| 2022-12-31 | $-1.77 | $0.81 | x |
| 2023-12-31 | $-2.05 | $0.81 | x |
| 2024-12-31 | $-1.15 | $0.81 | x |
| 2025-12-31 | $0.51 | $0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Coherus BioSciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -279.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -403.80%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 4.23x
- Recent ROE (-279.10%) is below the historical average (-169.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -359.20% | -1738.70% | 0.07x | 2.89x | $-33.94 Million |
| 2013 | 0.00% | -1949.65% | 0.06x | 0.00x | $-49.40 Million |
| 2014 | -130.52% | -280.12% | 0.17x | 2.80x | $-93.81 Million |
| 2015 | 0.00% | -743.18% | 0.14x | 0.00x | $-222.57 Million |
| 2016 | -657.94% | -66.98% | 1.07x | 9.22x | $-129.27 Million |
| 2017 | -779.99% | -15306.56% | 0.01x | 5.33x | $-241.22 Million |
| 2018 | 0.00% | -13453.66% | 0.02x | 0.00x | $-205.48 Million |
| 2019 | 85.38% | 25.23% | 0.87x | 3.89x | $79.31 Million |
| 2020 | 47.07% | 27.79% | 0.57x | 3.00x | $104.15 Million |
| 2021 | -293.78% | -87.92% | 0.48x | 6.95x | $-296.87 Million |
| 2022 | 0.00% | -138.24% | 0.44x | 0.00x | $-278.01 Million |
| 2023 | 0.00% | -92.48% | 0.41x | 0.00x | $-218.55 Million |
| 2024 | 0.00% | 10.68% | 0.60x | 0.00x | $41.71 Million |
| 2025 | -279.10% | -403.80% | 0.16x | 4.23x | $-176.39 Million |
Industry Comparison
This section compares Coherus BioSciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Coherus BioSciences Inc (CHRS) | $60.84 Million | -359.20% | 2.14x | $124.47 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more